Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Quizzes

Quiz
Rates of Amyloid Pathology in MS
11/19/2024
True or False: Patients with MS have a higher rate of amyloid pathology compared to control subjects.
True or False: Patients with MS have a higher rate of amyloid pathology compared to control subjects.
True or False: Patients with MS...
11/19/2024
Pharmacy Learning Network
Quiz
Comorbidity Risk of Alzheimer Disease and MS
10/22/2024
True or False: Among patients with MS, amyloid plaque accumulation in the brain was more likely in those with a typical MS history.
True or False: Among patients with MS, amyloid plaque accumulation in the brain was more likely in those with a typical MS history.
True or False: Among patients...
10/22/2024
Pharmacy Learning Network
Quiz
FDA Approval for Alzheimer Disease Treatments
10/21/2024
True or False: Lecanemab-IRMB (Leqembi™) is the second Alzheimer drug that has affected the course of the disease successfully in phase 3, had a low side effect profile and then got full FDA approval.
True or False: Lecanemab-IRMB (Leqembi™) is the second Alzheimer drug that has affected the course of the disease successfully in phase 3, had a low side effect profile and then got full FDA approval.
True or False: Lecanemab-IRMB...
10/21/2024
Pharmacy Learning Network

Advertisement

Quiz
Understanding the Link Between Multiple Sclerosis and Alzheimer Disease
10/03/2024
True or False: Patients with a typical multiple sclerosis (MS) history are more likely to accumulate amyloid plaques in the brain compared to those with atypical presentations.
True or False: Patients with a typical multiple sclerosis (MS) history are more likely to accumulate amyloid plaques in the brain compared to those with atypical presentations.
True or False: Patients with a...
10/03/2024
Pharmacy Learning Network
Quiz
Differences in Alzheimer Disease Treatment Options
09/26/2024
Which significant difference between donanemab and lecanemab was mentioned in the Phase III TRAILBLAZER-ALZ 2 study?
Which significant difference between donanemab and lecanemab was mentioned in the Phase III TRAILBLAZER-ALZ 2 study?
Which significant difference...
09/26/2024
Pharmacy Learning Network
Quiz
Alzheimer Disease Treatment Terminology
09/26/2024
What does ARIA-E stand for in Alzheimer disease treatment?
What does ARIA-E stand for in Alzheimer disease treatment?
What does ARIA-E stand for in...
09/26/2024
Pharmacy Learning Network

Advertisement

Quiz
Hemorrhaging Incidents in Alzheimer Disease Treatment
09/20/2024
True or False: A potential side effect noted in treating Alzheimer disease with lecanemab-IRMB is amyloid-related imaging abnormality type H (ARIA-H).
True or False: A potential side effect noted in treating Alzheimer disease with lecanemab-IRMB is amyloid-related imaging abnormality type H (ARIA-H).
True or False: A potential side...
09/20/2024
Pharmacy Learning Network
Quiz
Post-Treatment Alzheimer Disease Progression
09/18/2024
True or False: Amyloid plaque levels begin to rise again within 1 year of donanemab treatment.
True or False: Amyloid plaque levels begin to rise again within 1 year of donanemab treatment.
True or False: Amyloid plaque...
09/18/2024
Pharmacy Learning Network
Quiz
Anti-Amyloid Drugs for Treating Alzheimer Disease
09/12/2024
Quiz: According to findings from the Phase III TRAILBLAZER-ALZ 2 study, upon which the FDA approval of donanemab is based, what percentage of patients were able to discontinue the drug within a year?
Quiz: According to findings from the Phase III TRAILBLAZER-ALZ 2 study, upon which the FDA approval of donanemab is based, what percentage of patients were able to discontinue the drug within a year?
Quiz: According to findings from...
09/12/2024
Pharmacy Learning Network

Advertisement

Quiz
Alzheimer Disease Treatment Breakthroughs
08/27/2024
True or False: Lecanemab is the first Alzheimer's drug to successfully affect the course of the disease in phase 3 trials and receive full FDA approval.
True or False: Lecanemab is the first Alzheimer's drug to successfully affect the course of the disease in phase 3 trials and receive full FDA approval.
True or False: Lecanemab is the...
08/27/2024
Pharmacy Learning Network

Advertisement

Advertisement

Advertisement

Stay Informed & Sign Up Today

Pharmacy Learning Network Newsletter

Advertisement

Video Insights

Videos
David Rubin, MD, on JAK Inhibitors: Small But Mighty
11/22/2023
Dr Rubin reviews his presentation from the Advances in Inflammatory Bowel Disease regional meeting on the latest information on the safety and efficacy of Janus kinase inhibitors for the treatment of inflammatory bowel disease.
Dr Rubin reviews his presentation from the Advances in Inflammatory Bowel Disease regional meeting on the latest information on the safety and efficacy of Janus kinase inhibitors for the treatment of inflammatory bowel disease.
Dr Rubin reviews his...
11/22/2023
Pharmacy Learning Network
Videos
Advantages and Drawbacks of Lecanemab in Alzheimer Disease Treatment
11/10/2023
Dr Shulz discusses the FDA-approved lecanemab for the treatment of AD.
Dr Shulz discusses the FDA-approved lecanemab for the treatment of AD.
Dr Shulz discusses the...
11/10/2023
Pharmacy Learning Network
Videos
Immunosuppressants or Immunomodulators? Biologic Agents for Psoriasis
10/27/2023
In this exclusive interview, Dr Ronald Vender goes over the highly effective targeted biologic therapies used to treat psoriasis.
In this exclusive interview, Dr Ronald Vender goes over the highly effective targeted biologic therapies used to treat psoriasis.
In this exclusive interview, Dr...
10/27/2023
Pharmacy Learning Network
Videos
Application of Dupilumab to Pediatric Patients With Atopic Dermatitis
10/27/2023
In this feature video, Dr Abigail Cline discusses current literature to assess reported efficacies, side effects, and risks of using dupilumab to treat atopic dermatitis in pediatric patients.
In this feature video, Dr Abigail Cline discusses current literature to assess reported efficacies, side effects, and risks of using dupilumab to treat atopic dermatitis in pediatric patients.
In this feature video, Dr...
10/27/2023
Pharmacy Learning Network
Videos
Patient Considerations When Prescribing Lecanemab for Alzheimer Disease
10/06/2023
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
10/06/2023
Pharmacy Learning Network
Headshots of Chris Fausel, PharmD, MHA, BCOP; Erin Hamai Tom, PharmD, APh, MBA, BCACP; and Ryan Nix, PharmD, MMHC
Videos
Specialty Pharmacy Next: Focus on Distribution Processes, Data Utilization, New Drugs, and More
07/18/2023
In this roundtable, cochairs of Specialty Pharmacy Next gather to discuss pertinent topics on the agenda such as white and brown bagging practices and data usage for program growth, as well as who may benefit most from attending the meeting.
In this roundtable, cochairs of Specialty Pharmacy Next gather to discuss pertinent topics on the agenda such as white and brown bagging practices and data usage for program growth, as well as who may benefit most from attending the meeting.
In this roundtable, cochairs of...
07/18/2023
Pharmacy Learning Network
Videos
Leaders in Pharmacy Come Together to Discuss and Debate Oncology-Related Developments
06/28/2021
Chris Fausel, PharmD, Val Adams, PharmD, Kirollos Hanna, PharmD, and Lisa Holle, PharmD, cochairs of Great Debates and Updates Oncology Pharmacy, come together to discuss this new CPE event aimed at educating pharmacists interested in...
Chris Fausel, PharmD, Val Adams, PharmD, Kirollos Hanna, PharmD, and Lisa Holle, PharmD, cochairs of Great Debates and Updates Oncology Pharmacy, come together to discuss this new CPE event aimed at educating pharmacists interested in...
Chris Fausel, PharmD, Val Adams,...
06/28/2021
Pharmacy Learning Network
Expanded FDA Approval Improves Care Access, Rates of Flu Cases
Videos
Expanded FDA Approval Improves Care Access, Rates of Flu Cases
04/19/2021
Gregg Sylvester, MD, MPH, chief medical officer, and David Ross, vice president, commercial operations for North America, both at Seqirus, discuss the recent FDA approval for Flucelvax Quadrivalent, explain what the expanded indication means...
Gregg Sylvester, MD, MPH, chief medical officer, and David Ross, vice president, commercial operations for North America, both at Seqirus, discuss the recent FDA approval for Flucelvax Quadrivalent, explain what the expanded indication means...
Gregg Sylvester, MD, MPH, chief...
04/19/2021
Pharmacy Learning Network
Identifying Drug Diversion Differences in Retail Pharmacies Compared With Health Systems
Videos
Identifying Drug Diversion Differences in Retail Pharmacies Compared With Health Systems
12/28/2020
Tom Knight, founder and CEO, Invistics, identifies drug diversion differences in a hospital or health system versus a retail pharmacy, and explains what retail pharmacies can do to better detect and address drug diversion.
Tom Knight, founder and CEO, Invistics, identifies drug diversion differences in a hospital or health system versus a retail pharmacy, and explains what retail pharmacies can do to better detect and address drug diversion.
Tom Knight, founder and CEO,...
12/28/2020
Pharmacy Learning Network
Identifying Risks of Human Error, Workarounds in Pharmacy
Videos
Identifying Risks of Human Error, Workarounds in Pharmacy
12/22/2020
Matthew Grissinger, RPh, FISMP, FASCP, director of Error Reporting Programs, Institute for Safe Medication Practices, discusses how human error, various at-risk behaviors, as well as workarounds taken by staff members all impact outcomes and...
Matthew Grissinger, RPh, FISMP, FASCP, director of Error Reporting Programs, Institute for Safe Medication Practices, discusses how human error, various at-risk behaviors, as well as workarounds taken by staff members all impact outcomes and...
Matthew Grissinger, RPh, FISMP,...
12/22/2020
Pharmacy Learning Network

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use